Keyword: Lumena Pharmaceuticals
The deal reunites some of the management team and investor syndicate that worked on the liver disease drug at Lumena before selling out to Shire.
The series C sets Amplyx up to take its lead broad-spectrum antifungal candidate into phase 2 later this year.
Shire has been given a breakthrough designation from the FDA for its two experimental gastrointestinal meds SHP621 and SHP625, which should speed up the regulatory review process.
Shire's liver drug flunks its second test in a year.